Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts. Show more

101 Seaport Blvd., Boston, MA, 02210-2186, United States

https://www.seaporttx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

933.6M

52 Wk Range

$14.85 - $23.00

Previous Close

$17.44

Open

$17.41

Volume

199,065

Day Range

$17.31 - $18.13

Enterprise Value

760.1M

Cash

182.6M

Avg Qtr Burn

-20.17M

Insider Ownership

35.06%

Institutional Own.

28.37%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GlyphAllo/Glyph Allopregnanolone (SPT-300) (Neuroactive Steroid) Details Major Depressive Disorder	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Oral Prodrug) Details Generalized Anxiety Disorder	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Melatonergic Agonist) Details Generalized Anxiety Disorder	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Oral Prodrug) Details Generalized Anxiety Disorder With Sleep Disturbance	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAgo/Agomelatine (SPT-320) (Melatonergic Agonist) Details Generalized Anxiety Disorder	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GlyphAllo/Glyph Allopregnanolone (SPT-300) (Neuroactive Steroid) Details Driving Safety In Healthy Volunteers	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.